← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
tarlatamab
L01FX33
Forms & Strengths
- injection 20 mg/mL
- single-dose vial
Adult Dosing
- 1.2 mg/kg IV on day 1, 0.8 mg/kg IV on day 8, 0.8 mg/kg IV on day 15
- maintenance dose: 1.2 mg/kg IV every 2 weeks
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Relapsed or refractory multiple myeloma
- In combination with other antineoplastic agents
Mechanism of Action
- Selective bifunctional anti-BCMA antibody
- Simultaneously binds to BCMA and CD3, facilitating T-cell mediated killing of BCMA-expressing cells
Contraindications
- Hypersensitivity to tarlatamab or excipients
Adverse Reactions
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
- Infections
- Neurotoxicity
Drug Interactions
- Concomitant use with immunosuppressive agents may decrease efficacy
- Corticosteroids may reduce efficacy and increase risk of infections
Curated Content: Needs Vetting Before Put to Clinical Use